What is Green Bioactives?
Founded in 2018, Green Bioactives operates at the intersection of biotechnology and sustainable manufacturing. The company specializes in the research and experimental development of plant-derived bioactive compounds, providing a reliable and sustainable supply chain for the cosmetic, pharmaceutical, food, and agricultural industries. By utilizing advanced extraction and cultivation techniques, the firm addresses the critical need for high-purity, ethically sourced ingredients that meet the stringent regulatory and performance standards of modern global enterprises.
The company's market position is defined by its commitment to green chemistry and its ability to solve complex supply chain challenges for multinational corporations. As industries shift toward sustainable procurement, Green Bioactives provides the essential intellectual property and production capabilities required to replace synthetic or unsustainable traditional sources with high-performance, nature-derived alternatives.
How much funding has Green Bioactives raised?
Green Bioactives has raised a total of $3.2M across 1 funding round:
Angel/Seed
$3.2M
Angel/Seed (2022): $3.2M with participation from Milltrust International Group, Scottish Enterprise, Eos Advisory Partners, and Agtech Fund
Key Investors in Green Bioactives
Milltrust International Group
A specialist investment organization focusing on sustainable solutions across public and private markets, with a strong emphasis on food demand, technology, and climate change.
Scottish Enterprise
The national economic development agency of the Scottish Government, dedicated to fostering innovation and economic growth within the region.
Eos Advisory Partners
A professional advisory firm providing strategic financial and operational consulting to help companies improve performance and navigate complex capital markets.
What's next for Green Bioactives?
With the successful closure of this major strategic investment, Green Bioactives is set to prioritize the commercialization of its core product pipeline. The strategic roadmap includes scaling production facilities to meet the growing demand from the pharmaceutical and cosmetic sectors, alongside further investment in R&D to expand its library of bioactive compounds. The company will likely focus on deepening its partnerships with global distributors and manufacturers to integrate its sustainable solutions into mainstream product lines.
Furthermore, the firm is expected to leverage its current capital position to enhance its operational infrastructure, ensuring that its research-led approach remains competitive in a rapidly evolving biotechnology landscape. By focusing on long-term value creation and sustainable growth, Green Bioactives is well-equipped to navigate the complexities of the global bio-economy while maintaining its commitment to environmental stewardship and scientific excellence.
